Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo plus Yervoy for the ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Replimune Group (REPL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...